CJC-1295 DAC Dosage Chart: Research Dosing Reference

There is no FDA-approved CJC-1295 DAC dosage chart for personal use. The original human trials used weight-based cohorts rather than a standard fixed 1–2 mg weekly dose. A useful chart identifies the actual study exposure and its limitations without converting it into a fitness regimen.

What CJC-1295 DAC Is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Instead of supplying growth hormone directly, it binds to GHRH receptors and prompts the pituitary to release the body's own GH.

The "DAC" portion is a Drug Affinity Complex, a maleimide linker that attaches to albumin in the bloodstream. Albumin binding slows clearance dramatically and stretches the half-life from minutes to days.

The approximately 6–8-day figure comes from healthy human adults given the DAC compound: Teichman and colleagues estimated a half-life of 5.8–8.1 days after a single subcutaneous administration. It is not an animal-only estimate or a value established for every product labeled CJC-1295.

CJC-1295 DAC: Published Exposure and Unvalidated Claims

The 2006 randomized, placebo-controlled trials followed healthy adults for 28 or 49 days. Single-dose cohorts received 30, 60, 125, or 250 mcg/kg; the repeat-dose study used two or three administrations at weekly or biweekly intervals. These were monitored research protocols, not an approved personal dosing schedule.

Source or design	Exposure described	Frequency/context	Interpretation
Single-dose trial	30, 60, 125, 250 mcg/kg	One administration	Healthy-adult research, not personal starting doses
Repeat-dose trial	Study-specific weight-based cohorts	Two or three administrations, weekly/biweekly	Short monitored exposure
Fixed 1–2 mg/week chart	Not the original cohort definition	Forum/vendor claim needs its source	Not a validated standard
No-DAC schedule	Distinct compound	Requires its own evidence	Cannot inherit DAC study results
No-DAC/ipamorelin blend	Multiple constituents and amounts	Combination not validated here	No approved mixed regimen

Check units before comparing reports: 1 mg equals 1,000 mcg. Both forms can be expressed in either unit, and a different unit label does not itself determine potency or safety.

How CJC-1295 DAC Compares With the No-DAC Version

The material marketed as CJC-1295 no DAC or Mod GRF (1-29) lacks the albumin-binding modification and is distinct from the DAC compound studied in the cited human trials. FDA’s assessment cautions against transferring the DAC pharmacological profile to non-DAC forms; it does not establish a universal 30-minute human half-life or a daily regimen for all such products.

Feature	DAC compound	No-DAC material
Half-life	5.8–8.1-day healthy-adult estimate	Not established by the DAC trial
Amount	Original cohorts used mcg/kg	No approved personal amount here
Frequency	Trial-specific exposure	No automatically required daily schedule
Mass units	mg or mcg with correct conversion	mg or mcg with correct conversion
Albumin binding	Yes (the DAC group)	No
Combination	No validated retail blend in cited DAC trials	Own compatibility and outcome evidence needed

A side-by-side chart should distinguish identity and evidence, rather than prescribe weekly DAC and multiple-daily no-DAC schedules.

Weekly Dosing and Timing Claims

There is no FDA-approved CJC-1295 DAC dose or validated bodybuilding regimen. A fixed 1–2 mg weekly range should not be presented as the dose established by the original weight-based human trials. Research exposure cannot be converted into a safe personal amount from age, sex, weight, or vial size alone.

The cited trials do not establish bedtime administration, a meal-free interval, or timing around workouts as a way to improve bodybuilding outcomes. Normal GH physiology alone does not validate a nightly or fasting schedule for a long-acting investigational compound.

No defined set of original Reddit posts, dates, verified products, or participant records is supplied here, so this article cannot rank common protocols or describe a forum consensus. A post can identify a claim worth checking, but does not establish its frequency, cause, or safety.

A forum post may document one reported exposure. Without verified material, controlled comparison, and clinical context, it cannot establish a safe dose, typical response, or market-wide practice.

Blends, Stacks, and Related Protocols

Ipamorelin acts through the ghrelin receptor pathway, whereas CJC-1295 acts through the GHRH receptor pathway. Different mechanisms do not establish a safe combination dose, compatibility in one vial, or superior sleep, recovery, or body composition. The cited DAC trials did not validate the online CJC-1295/ipamorelin schedules.

A cjc-1295 no dac ipamorelin 10mg blend dosage calculation needs the amount of each ingredient and final solution volume. Total label mass alone does not establish a 5 mg/5 mg split or a personal dose. Use a peptide unit converter to check mg and microgram arithmetic; a correct conversion does not validate a dosage chart's clinical premise.

A fixed-ratio mixture also requires compatible formulation and independent evidence for the proposed use. Frequency cannot be validated by the packaging.

Safety and Legal Status

CJC-1295 has no FDA-approved human indication. A “research use only” label does not itself authorize human treatment or settle whether a particular sale, import, or possession is lawful. Product claims, intended use, compounding requirements, and jurisdiction matter; an ordinary retail research vial is not an approved prescription medicine.

The short human studies reported injection-site reactions, flushing or warmth, headache, and gastrointestinal symptoms. FDA also identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes limited clinical data and impurity/immunogenicity concerns. Neither a tolerable first exposure nor a normal blood test establishes long-term safety. Related research also covers CJC-1295 No DAC Dosage Chart: Typical Research Doses and CJC 1295 DAC Dosage Per Week: Reddit Insights.

• A lot-matched report can document the sample tested, method, date, and result. It does not prove every vial has the same content, that a supplier-submitted sample was independently purchased, or that the material is sterile or clinically safe. Acceptance criteria should follow the laboratory’s intended assay, rather than a universal 98% purity threshold.
• Understand that a "research chemical" label means the product is not intended for human consumption.
• The 2026 WADA list explicitly includes CJC-1295 as prohibited in and out of competition.
• Talk to a licensed healthcare professional before considering any use in humans.

Key Takeaways

• The original human studies used controlled weight-based DAC exposure, not a validated fixed weekly fitness dose.
• The approximately 6–8-day half-life is a human DAC result and should not be transferred to no-DAC products.
• A shared product name does not establish equal identity, interchangeable amounts, or an approved daily schedule.
• CJC-1295 DAC is not FDA-approved for human use in the United States.
• Neither a dosage chart nor forum anecdotes replace evidence for a safe and effective personal regimen.

COMMON QUESTIONS

Frequently Asked Questions

What is the typical CJC-1295 DAC dosage per week?

There is no validated personal-use answer. Controlled healthy-adult studies investigated specific weight-based exposures and short repeat administration; they did not establish a maintenance or fitness regimen. Discuss an endocrine or health concern with a qualified clinician rather than deriving a dose from a forum range.

Is CJC-1295 DAC the same as CJC-1295 no DAC?

The DAC compound carries an albumin-binding modification; no-DAC materials are distinct and need their own identity and clinical evidence. The cited human DAC studies do not establish a universal 30-minute no-DAC half-life, an approved daily regimen, or a comparative safety advantage.

Is CJC-1295 DAC legal in the US?

CJC-1295 has no FDA-approved human indication. A research-use label does not automatically establish that a particular purchase, import, sale, possession, or human use is lawful. Intended use, product claims, compounding requirements, and jurisdiction must be assessed separately.